Clinical Trials
3 trialsNCT02988843 2020-12-10
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT02689219 2019-12-10
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Indiana University
Phase 2 Terminated
NCT01851200 2018-02-07
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Fondazione Michelangelo
Phase 2 Completed